Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care — Cancer Care Ontario Clinical Practice Guideline

Browman, 1995, The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation, J Clin Oncol, 13, 502, 10.1200/JCO.1995.13.2.502 Browman, 1998, Progress of clinical oncology guidelines development using the practice guidelines development cycle: the role of practitioner feedback, J Clin Oncol, 16, 1226, 10.1200/JCO.1998.16.3.1226 Guideline 3-14v2: Bone health and bone-targeted therapies for prostate cancer. Available at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=364328 [Accessed 30 September 2016]. Papaioannou, 2010, 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary, Can Med Assoc J, 182, 1864, 10.1503/cmaj.100771 Gralow, 2009, NCCN Task Force Report: bone health in cancer care, J Natl Compr Cancer Network, 7, S1, 10.6004/jnccn.2009.0076 Winters-Stone, 2014, Skeletal response to resistance and impact training in prostate cancer survivors, Med Sci Sports Exercise, 46, 1482, 10.1249/MSS.0000000000000265 Nilsen, 2015, Effects of strength training on body composition, physical functioning and quality of life in prostate cancer patients during androgen deprivation therapy, Acta Oncol, 54, 1805, 10.3109/0284186X.2015.1037008 Cormie, 2015, Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial, BJU Int, 115, 256, 10.1111/bju.12646 Santa Mina, 2012, Group exercise versus personal training for prostate cancer patients: a pilot randomized trial, J Cancer Ther, 3, 146 Guideline 19-5: Exercise for people with cancer. Available at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=342805 [Accessed 10 August 2016]. Smith, 2009, Denosumab in men receiving androgen-deprivation therapy for prostate cancer, N Engl J Med, 361, 745, 10.1056/NEJMoa0809003 Ding, 2013, Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis, Asian Pacific J Cancer Prev, 14, 3337, 10.7314/APJCP.2013.14.5.3337 Kachnic, 2013, RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients, Prostate Cancer Prostatic Dis, 16, 382, 10.1038/pcan.2013.35 Wells, 2008, Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst Rev, 1, CD004523 Wells, 2008, Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst Rev, 1, CD003376 Wells, 2008, Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst Rev, 1, CD001155 Chen, 2015, Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials, Osteoporos Int, 26, 2355, 10.1007/s00198-015-3148-4 Rodrigues, 2007, Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study, Int J Urol, 14, 317, 10.1111/j.1442-2042.2006.01721.x Kearns, 2010, Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8, Support Care Cancer, 18, 321, 10.1007/s00520-009-0655-x Greenspan, 2008, Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy, J Clin Oncol, 26, 4426, 10.1200/JCO.2007.15.1233 Israeli, 2007, The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy, Clin Genitourin Cancer, 5, 271, 10.3816/CGC.2007.n.003 Diamond, 2001, The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study, Cancer, 92, 1444, 10.1002/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M Satoh, 2009, Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma, Cancer, 115, 3468, 10.1002/cncr.24404 Wang, 2013, Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases, Med Oncol, 30, 657, 10.1007/s12032-013-0657-x Summary Minutes of the Oncologic Drugs Advisory Committee Meeting February 8, 2012. Available at: www.fda.gov/downloads/Advisorycommittees/CommitteesMeetingMaterials/Drugs%20/OncologicDrugsAdvisoryCommittee/UCM293709.pdf [Accessed 10 August 2016]. Wirth, 2015, Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS), Eur Urol, 67, 482, 10.1016/j.eururo.2014.02.014 Mason, 2007, Oral sodium clodronate for nonmetastatic prostate cancer–results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873), J Natl Cancer Inst, 99, 765, 10.1093/jnci/djk178 Smith, 2012, Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, Lancet, 379, 39, 10.1016/S0140-6736(11)61226-9 Zimmerman, 2015, Revision of the NIST standard for (223)Ra: new measurements and review of 2008 data, J Res Natl Inst Stand Technol, 120, 37, 10.6028/jres.120.004 Guideline 3-15: Systemic therapy in men with metastatic castration-resistant prostate cancer. Available at: https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=318883 [Accessed 10 August 2016]. Lutz, 2011, Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline, Int J Radiat Oncol Biol Phys, 79, 965, 10.1016/j.ijrobp.2010.11.026 Saad, 2015, The 2015 CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC), Can Urol Assoc J, 9, 90, 10.5489/cuaj.2526 Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6 Ford, 2013, Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis, Eur J Cancer, 49, 416, 10.1016/j.ejca.2012.07.016 Ueno, 2013, Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study, Anticancer Res, 33, 3837 Smith, 2014, Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance), J Clin Oncol, 32, 1143, 10.1200/JCO.2013.51.6500 Dearnaley, 2003, A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial), J Natl Cancer Inst, 95, 1300, 10.1093/jnci/djg038 Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458 Small, 2003, Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer, J Clin Oncol, 21, 4277, 10.1200/JCO.2003.05.147 Yuen, 2006, Bisphosphonates for advanced prostate cancer, Cochrane Database Syst Rev, 4, CD006250 Saad, 2004, Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J Natl Cancer Inst, 96, 879, 10.1093/jnci/djh141 Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 Sartor, 2014, Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial, Lancet Oncol, 15, 738, 10.1016/S1470-2045(14)70183-4 Nilsson, 2007, Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study, Lancet Oncol, 8, 587, 10.1016/S1470-2045(07)70147-X Roque, 2011, Radioisotopes for metastatic bone pain, Cochrane Database Syst Rev, 7, CD003347 Quilty, 1994, A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer, Radiother Oncol, 31, 33, 10.1016/0167-8140(94)90411-1 Oosterhof, 2003, Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group, Eur Urol, 44, 519, 10.1016/S0302-2838(03)00364-6 Nilsson, 2005, Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study, J Pain Symptom Manage, 29, 352, 10.1016/j.jpainsymman.2004.07.008 Pan, 2014, Docetaxel with or without zoledronic acid for castration-resistant prostate cancer, Int Urol Nephrol, 46, 2319, 10.1007/s11255-014-0824-9 Nilsson, 2013, Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases, Clin Genitourin Cancer, 11, 20, 10.1016/j.clgc.2012.07.002 Dearnaley, 2009, Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials, Lancet Oncol, 10, 872, 10.1016/S1470-2045(09)70201-3 Kylmala, 1993, Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group, Eur J Cancer, 29A, 821, 10.1016/S0959-8049(05)80417-4 Ernst, 2003, Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain, J Clin Oncol, 21, 3335, 10.1200/JCO.2003.03.042 Figg, 2005, A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases, J Urol, 173, 790 Meulenbeld, 2012, Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic castration resistant prostate cancer (CRPC), the Netherlands Prostate Study (NePro), Eur J Cancer, 48, 2993, 10.1016/j.ejca.2012.05.014 James, 2016, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 387, 1163, 10.1016/S0140-6736(15)01037-5 Himelstein, 2015, CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer, J Clin Oncol, 33